ReviewOncotarget2017
Cancer and the kidney: dangereoux liasons or price paid for the progress in medicine?
Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Blood-based biomarkers of protein digestibility, utilization, and nitrogen excretion in animals: Concepts, evidence, and applications.Veterinary and animal science · 2026Review
- Impact of cardiometabolic health on treatment outcomes in early-stage triple-negative breast cancer receiving chemoimmunotherapy.Breast cancer research and treatment · 2026Article
- Malignancy in Dialysis Patients-How Serious Is the Problem, Especially in Relation to Waiting List Status?Cancers · 2025Article
- A randomized controlled trial comparing pioglitazone and metformin prior to in vitro fertilization in polycystic ovary syndrome - associated infertile women: impact on pregnancy rates.Annals of medicine and surgery (2012) · 2024Article
- Cancer before and after the start of hemodialysis and association with mortality - an Eastern-European multicenter study.Renal failure · 2023Article
- Machine learning for acute kidney injury: Changing the traditional disease prediction mode.Frontiers in medicine · 2023Review
- Molecular Mechanisms and Biomarkers Associated with Chemotherapy-Induced AKI.International journal of molecular sciences · 2022Review
- Risk of malignancy in patients with chronic kidney disease.PloS one · 2022Article
- Prediction models for acute kidney injury in patients with gastrointestinal cancers: a real-world study based on Bayesian networks.Renal failure · 2020Article
- Protective effect of tolvaptan against cyclophosphamide-induced nephrotoxicity in rat models.Pharmacology research & perspectives · 2020Article
- Why is renal impairment associated with poorer cancer specific survival in breast cancer patients?: a comparison with patients with other comorbidities.International journal of clinical oncology · 2020Article
- Immune Dysfunction in Uremia 2020.Toxins · 2020Review
- Adhesion GPCRs in Kidney Development and Disease.Frontiers in cell and developmental biology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A long time ago, the links between renal disease and malignancy were observed, however, quite recently, their importance was recognized and 'new' subspecialty in nephrology, namely 'onconephrology' was established. In the XXI century, patients with malignancy make up the most growing number of the subjects seen for nephrology consult and/or critical care nephrology services. A plethora of renal problems may be found in patients with malignancy. They may influence not only their short-term outcomes but also the adequate therapy of the underlying oncological problem. Thus, all these kidney-related issues pose an important challenge for both specialities: oncology and nephrology. In the review a spectrum of acute and chronic renal injury caused by the malignancy is presented as well as the associations between renal disease and cancer. Assessment of kidney function and its importance in patients with malignancy is also discussed as medical oncologists should check the appropriate dose of chemotherapeutic drugs in relation to the actual renal function before prescribing them to the patients. Moreover, effects of kidney function on outcomes in oncology is presented. In addition, nephrology services should better understand both the biology of malignancy with its treatment to become a valuable part treating team to yield the best possible outcome. It is important for nephrology services to be acknowledged and to take an active participation in care of oncology patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.